Literature DB >> 15914325

Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions.

Cartesio D'Agostini1, Francesca Pica, Giuseppe Febbraro, Sandro Grelli, Carlo Chiavaroli, Enrico Garaci.   

Abstract

We report that OM-174, a purified water soluble diphosphorylated and triacetylated lipid A derived from E. coli, is able to reduce tumour progression and to prolong the survival of mice in the B16 melanoma experimental model. At the doses employed in our study OM-174 had an antitumour activity comparable to that of a single high dose of CY. More striking effects were achieved by means of the combination of the two agents in a protocol consisting of a single administration of CY (200 mg/kg) followed by five injections of OM-174 (1 mg/kg). Immunological studies of treated and control mice revealed that the antitumour activity of OM-174, alone or in combination with CY, is mediated by the stimulation of natural killer (NK) and cytotoxic T lymphocyte (CTL) responses as well as by a significant increase in the absolute number of NK1.1, CD4 and CD8 positive cells. OM-174 is thus candidate for association with cytostatic drugs in chemo-immunotherapy protocols.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15914325     DOI: 10.1016/j.intimp.2005.02.013

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  19 in total

1.  Immunomodulatory and anticancer effects of Pituranthos tortuosus essential oil.

Authors:  Mounira Krifa; Hala El Mekdad; Nawel Bentouati; Antonio Pizzi; Kamel Ghedira; Mohamed Hammami; Salah Edin El Meshri; Leila Chekir-Ghedira
Journal:  Tumour Biol       Date:  2015-02-08

2.  In vitro and in vivo anticancer activity of a synthetic glycolipid as Toll-like receptor 4 (TLR4) activator.

Authors:  Yong-Shiang Lin; Li-De Huang; Chao-Hsiung Lin; Po-Hsiung Huang; Yu-Jen Chen; Fen-Hwa Wong; Chun-Cheng Lin; Shu-Ling Fu
Journal:  J Biol Chem       Date:  2011-09-23       Impact factor: 5.157

Review 3.  Targeting Toll-like receptors: emerging therapeutics?

Authors:  Elizabeth J Hennessy; Andrew E Parker; Luke A J O'Neill
Journal:  Nat Rev Drug Discov       Date:  2010-04       Impact factor: 84.694

4.  Toll-like receptor polymorphisms in allogeneic hematopoietic cell transplantation.

Authors:  Brian Kornblit; Christian Enevold; Tao Wang; Stephen Spellman; Mike Haagenson; Stephanie J Lee; Klaus Müller
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-20       Impact factor: 5.742

5.  The Potent Humanin Analogue (HNG) Protects Germ Cells and Leucocytes While Enhancing Chemotherapy-Induced Suppression of Cancer Metastases in Male Mice.

Authors:  YanHe Lue; Ronald Swerdloff; Junxiang Wan; Jialin Xiao; Samuel French; Vince Atienza; Victor Canela; Kevin W Bruhn; Brian Stone; Yue Jia; Pinchas Cohen; Christina Wang
Journal:  Endocrinology       Date:  2015-09-18       Impact factor: 4.736

6.  TLR4/IFNγ pathways induce tumor regression via NOS II-dependent NO and ROS production in murine breast cancer models.

Authors:  Myriam Lamrani; Nejia Sassi; Catherine Paul; Nadhir Yousfi; Jean-Luc Boucher; Nolwenn Gauthier; Jérôme Labbé; Cédric Seignez; Cindy Racoeur; Anne Athias; Romain Guerreiro; Catherine Vergely; Luc Rochette; Ali Bettaieb; Jean-François Jeannin
Journal:  Oncoimmunology       Date:  2015-12-29       Impact factor: 8.110

Review 7.  The anticancer immune response: indispensable for therapeutic success?

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Fabrice André; Antoine Tesniere; Guido Kroemer
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

8.  In vitro and in vivo anti-melanoma effects of Daphne gnidium aqueous extract via activation of the immune system.

Authors:  Fadwa Chaabane; Nadia Mustapha; Imen Mokdad-Bzeouich; Aicha Sassi; Soumaya Kilani-Jaziri; Marie-Geneviève Dijoux Franca; Serge Michalet; Mayssa Fathallah; Mounira Krifa; Kamel Ghedira; Leila Chekir-Ghedira
Journal:  Tumour Biol       Date:  2015-12-04

9.  Trial Watch: Experimental Toll-like receptor agonists for cancer therapy.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

10.  Prognostic Biomarker-Based Identification of Drugs for Managing the Treatment of Endometrial Cancer.

Authors:  Dilraj Kaur; Chakit Arora; Gajendra Pal Singh Raghava
Journal:  Mol Diagn Ther       Date:  2021-06-22       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.